Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7301 - 7325 of 8267 in total
Eluforsen is under investigation in clinical trial NCT02532764 (Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients).
Investigational
Matched Description: … Eluforsen is under investigation in clinical trial NCT02532764 (Dose Escalation Study of QR-010 in Homozygous …
Nedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer).
Investigational
Matched Description: … Nedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine …
Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).
Investigational
Matched Description: … Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination …
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Investigational
Matched Description: … Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With …
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of
Rusfertide is a hepcidin mimetic currently being developed by Protagonist Therapeutics for the treatment of polycythemia vera and beta-thalassemia.
Investigational
Matched Description: … Rusfertide is a hepcidin mimetic currently being developed by Protagonist Therapeutics for the treatment of
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Matched Description: … SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis …
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
Matched Description: … PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated …
RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.
Investigational
Matched Description: … RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal …
Cefetamet pivoxil is under investigation in clinical trial NCT04664803 (Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis).
Investigational
Matched Description: … Cefetamet pivoxil is under investigation in clinical trial NCT04664803 (Safety and Efficacy of Cefecin …
AGI-134 is under investigation in clinical trial NCT03593226 (Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour).
Investigational
Matched Description: … AGI-134 is under investigation in clinical trial NCT03593226 (Study to Evaluate Safety & Tolerability of
Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of...
Investigational
Matched Description: … Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt ... It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients …
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Description: … of inflammatory pain, itch and visceral pain. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment …
Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may...
Investigational
Matched Description: … It is found in the majority of aquatic organisms with red pigment. ... Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. …
Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit
Matched Description: … Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America ... Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl …
WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of...
Experimental
Matched Description: … is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of ... is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of
Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially...
Investigational
Matched Description: … The structure of vMIP consists of 71 residues and is a monomer under most conditions. …
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine. Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … and immunogenicity of the vaccine. ... cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of ... As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety …
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in...
Investigational
Matched Description: … The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations ... Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and ... As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical …
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
Experimental
Matched Description: … These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin. …
Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)).
Investigational
Matched Description: … Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination …
Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation . It is characterized by antifibrotic, fibrolytic, and immunomodulatory properties .
Investigational
Matched Description: … Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight …
BT200 (Rondoraptivon pegol) is a PEGylated anti-von Willebrand factor (VWF) aptamer targeted against the VWF A1 domain. It is under investigation for the treatment of von Willebrand disease and hemophilia A.
Investigational
Matched Description: … [A261491] It is under investigation for the treatment of von Willebrand disease and hemophilia A. …
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
Matched Description: … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases …
Toluene is a colorless, liquid that is immiscible in water. It is a mono-substituted benzene derivative used in veterinary medicine as a treatment for various parasites in dogs and cats.
Vet approved
Displaying drugs 7301 - 7325 of 8267 in total